JP Morgan Chase’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NRIX
JP Morgan Chase's NRIX Position: Q3 2026 in Review
JP Morgan Chase increased its Nurix Therapeutics (NRIX) stake by 660% in Q3 2026, buying an estimated $8.01M and bringing the position to 369,991 shares worth $8.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2986.
JP Morgan Chase first reported a position in NRIX in Q3 2020 and has held it in 25 quarters since. 157 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.
- JP Morgan Chase held 369,991 shares of Nurix Therapeutics worth $8.76M as of Q3 2026.
- JP Morgan Chase bought 321,299 Nurix Therapeutics shares in Q3 2026, an estimated $8.01M.
- Nurix Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #2986 holding.
- JP Morgan Chase first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 25 quarters since.
- 157 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.